NewcelX Ltd.NCEL
Price (close)
$2.89
Market cap
$13.9M
P/E
—
Revenue (FY)
—
Net income
-$8.3M
Dividend yield
—
1-year total return
-86.0%
Net margin
—
Revenue growth
—
Debt / equity
0.05x
What NewcelX Ltd. does.
focused on developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform
Replace, restore and repair the functionality of diseased and malfunctioning cells in various degenerative diseases by transplantation of healthy and functional cells;
the DOXA small molecules platform for clinical development of drug candidates, primarily for narcolepsy, neuroinflammation and DANS
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$2.9M | -$11.9M | -$16.5M | -$3.3M | -$7.2M | -$8.3M |
| Free cash flow | — | -$15.0M | — | -$3.5M | -$1.1M | -$2.8M |
More on NCEL.
- NewcelX Ltd. summary
- NewcelX Ltd. financial statements
- NewcelX Ltd. key metrics
- NewcelX Ltd. health scores and style box
- NewcelX Ltd. earnings
- NewcelX Ltd. dividends
- NewcelX Ltd. valuation
- NewcelX Ltd. ownership and insiders
- NewcelX Ltd. peers
Figures from NewcelX Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.